[Advances in Multimodality Therapy of Lung Cancer].

Xinghao Ai,Shun Lu,Meilin Liao

DOI: https://doi.org/10.3779/j.issn.1009-3419.2003.06.07

2004-01-01

Abstract:Multimodality therapy has been gradually taken to be the principle of therapy on lung cancer, and some new developments were seen followed by improvement of various discipline of therapies in recent years. Surgical multimodality therapy was indicated for operable stage Ⅰ-Ⅲ lung cancer. According to the peri-operative duration, it included:1) neoadjuvant chemotherapy : it was employed for inoperable stage Ⅲ NSCLC, a better survival was seen in the group treated with neoadjuvant chemotherapy, but it would reguire more multicenter randomized studies to prove it. 2) adjuvant chemotherapy: better survival rate was seen in 1 867 cases of NSCLC treated with adjuvant chemotherapy combined with complete resection as reported in ASCO and WCLC of 2003, 3-4 cycles of platinum-contained schedule were used as adjuvant chemotherapy, the 5-yr survival rates were 40% and 45%, respectively. 3) pre-operative and post-operative radiotherapy showed no benefit to the survival rate, but post-operative radiotherapy might reduce the local relapse. Non-surgical multimodality therapy, 1) chemoradiotherapy (CRT): CRT was indicated for local advanced NSCLC, concurrent CRT had a tendency to be superior to sequential CRT. 2) chemotherapy was the main discipline for stage Ⅳ lung cancer, platinum-contained chemotherapy schedule would be the first choice for metastasized lung cancer, doublet chemotherapy schedule was superior to single agent and triplet combination. At present, EGFR-TKI was the common used target therapy medicine for NSCLC , for example, Iressa, Tarceva , it can be used as the 2nd and 3rd line regimens, the response rate was around 12%-19%,and 40% was with symptomatic improvement.